

26<sup>th</sup> -27<sup>th</sup> May 2022 - University of Sheffield - UK

## Meeting venue:

Inox - Level 5, Students' Union Building Durham Road, Sheffield S10 2TG, UK  
<http://inoxdine.co.uk/>

## SCIENTIFIC MEETING - 26<sup>th</sup> May 2022 (Only INTEGRATA members, fellows and AB)

15 min presentation each fellow + 5 min discussion

### 09.00-09.10 Welcome and Introduction

Patrick Herr- University of Sheffield, UK

Alessio Nencioni - INTEGRATA coordinator - Università degli Studi di Genova, Italy

### SESSION I: Development and/or *in vitro* testing of new NAMPT and NAPRT inhibitors

#### 09.10-09.30 Biochemical and cellular effects of NAPRT inhibitors in PDAC cells

Mochammad Ichsan - Universität Bonn, Germany

#### 09.30-09.50 Biochemical and cellular effects of NAMPT inhibitors in haematological cancer cells

Paulina Binieka - Centre Hospitalier Universitaire Vaudois, Switzerland

#### 09.50-10.10 New FK866 analogues, NAMPT inhibitors

Simone Fratta - Universidad de Sevilla, Spain

#### 10.10-10.30 New compounds circumventing resistance to NAMPT inhibition

Ágata Carreira - Università degli Studi di Trento, Italy

#### 10.30-10.50 New NAMPT inhibitors with imino-C-glycoside structures

Irene Conforti - Université de Montpellier, France

#### 10.50-11.05 *Coffee break*

#### 11.05-11.25 New NAPRT inhibitors

Jorge Sus Franco - Innovamol Consulting, Italy

#### 11.25-11.45 NAD precursor-depleted diets as a means to sensitize cancer cells to NAMPT inhibitors and chemotherapeutics

Moustafa Ghanem - Università degli Studi di Genova, Italy

### SESSION II: Development and *in vitro* testing of ADCs of NAMPT inhibitors

#### 11.45-12.05 ADCs of NAMPT inhibitors with anticancer activity

Pablo Ruedas-Batuecas - Heidelberg Pharma Research GmbH, Germany

### SESSION III: Development and *in vitro* testing of anti-eNAMPT and of anti-eNAPRT neutralizing Abs

#### 12.05-12.25 Neutralizing anti-eNAMPT Abs

Elise Semerena, Novimmune - Light Chain Bioscience, Switzerland

#### 12.25-14.00 *Lunch*



26<sup>th</sup> -27<sup>th</sup> May 2022 - University of Sheffield - UK**SESSION IV: Development and *in vitro* testing of SIRT6, TRPM2, NUDT22 and CD73 inhibitors****14.00-14.20 New SIRT6 inhibitors**

Elena Abbotto - Università degli Studi di Genova, Italy

**14.20-14.40 New NUDT22 inhibitors**

Melanie Walter - University of Sheffield, United Kingdom

**14.40-15.00 New CD73 inhibitors**

Benjamin Gyau - Università degli Studi di Torino, Italy

**15.00-15.20 New TRPM2 inhibitors**

Swati Balasheb Ohol - Universitätsklinikum Hamburg-Eppendorf, Germany

**SESSION V: Fingerprinting/pre-formulation, formulation, PK and biodistribution studies of NAD-lowering compounds and inhibitors of NAD/nucleotide signalling****15.20-15.40 In vivo metastasis and angiogenesis imaging as a reading frame for NAMPT inhibitor activity**

Burak Kizil - Université de Genève, Switzerland

**15.40-16.00** *Coffee break***MANAGEMENT MEETING****16.00-17.00** • **Progress of the project**

- **Potential issues in project activities, actions for completing the programme**
- **Possible project extension**
- **Next deadlines of the project, final reporting**
- **General discussion**

**20.00** *Dinner* (including invited speakers for the next day)

26<sup>th</sup> -27<sup>th</sup> May 2022 - University of Sheffield - UK

## WORKSHOP “Metabolic targets for cancer therapy” - 27<sup>th</sup> May 2022 (Symposium open also to external participants)

**09.00-09.30 Development of ectonucleotidase inhibitors as tools and drugs**  
Christa Muller - Universität Bonn, Germany

**09.30-10.00 Is PARG a better target than PARP for cancer therapy ?**  
Helen Bryant - University of Sheffield, United Kingdom

**10.00-10.30 Plasticity of Serine Metabolism in context of Cancer Cell Invasion and Metastasis**  
Johannes Meiser - Luxembourg Institute of Health, Luxembourg

**10.30-10.45** *Coffee break*

**10.45-11.15 Ex Vivo DEtermined caNcer Therapy (EVIDENT)**  
Greg Wells - University of Sheffield, United Kingdom

**11.15-11.45 TBA**  
Antonella Spinazzola - University College London, UK

**11.45-12.15 Linking metabolism to epigenetics and cancer, one gene at a time**  
Raul Mostovlasky - Massachusetts General Hospital, USA (*on line*)

**12.15-14.00** *Lunch*

**14.00** **Departures**